Scienture Holdings, Inc Stock Price, News & Analysis

SCIENTURE (NASDAQ: SCNX) announced a strategic collaboration with BlinkRx to expand national access to Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026. The U.S. losartan market totals about $245M in annual sales with roughly 71 million prescriptions (IQVIA MAT Sept 2025). BlinkRx reports it helps 52% more patients start therapy and keeps them on medication 40% longer, which Scienture says may increase starts, duration, and affordability for patients needing suspension formulations.

SCIENTURE HOLDINGS (NASDAQ: SCNX) announced management will participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9–10, 2025. Narasimhan Mani, President and co-CEO, will present at 2:00 PM ET on December 9. Shankar Hariharan, Executive Chairman and co-CEO, will join one-on-one investor meetings on December 10. A live webcast of the presentation is available at the conference link and a replay will be posted on the company’s investor site under Events and Presentations. The two-day event features Day 1 webcasts and Day 2 one-on-one investor meetings for pre-qualified investors.

SCIENTURE (NASDAQ: SCNX) reported Q3 2025 results and a business update on November 13, 2025. The company launched Arbli™, the first FDA-approved ready-to-use liquid formulation of losartan, and began commercial sales.

Q3 2025 vs Q3 2024: net revenue rose from ~$65K to $590K, and gross profit increased from ~$4K to $575K. Arbli was added to national payor formularies covering >100 million lives and secured GPO agreements reaching >2,500 institutions (~20% of U.S. institutional market). Post-quarter, the company reduced outstanding debt and reported cash of >$8 million as of November 13, 2025. Management plans a commercial launch of REZENOPY® in Q1 2026.

Scienture (NASDAQ: SCNX) announced that Arbli™ (losartan potassium) oral suspension, 10 mg/mL was added to formularies of key national payors, expanding availability to over 100 million covered lives in the United States.

Arbli is the first FDA‑approved ready‑to‑use oral suspension of losartan potassium. According to IQVIA (MAT June 2025), the U.S. losartan market is approximately $256 million in annual sales with >71 million prescriptions per year, representing a commercial opportunity. The company said plan design and utilization management may affect individual out‑of‑pocket costs.

SCIENTURE (NASDAQ: SCNX) announced the start of commercial sales and fulfillment of initial orders for Arbli™ (losartan potassium) Oral Suspension 10 mg/mL, the first FDA‑approved ready‑to‑use losartan oral suspension.

Key commercial facts: the U.S. losartan market is ~$256M annual sales with ~71M prescriptions (IQVIA, MAT June 2025). Scienture launched a multi‑channel promotional campaign, finalized PBM‑led GPO agreements, and executed multiple GPO contracts expanding access to >2,500 healthcare institutions, with estimated potential penetration of 20% of the U.S. institutional market.

Scienture Holdings (NASDAQ: SCNX) announced that Arbli™ (losartan potassium) Oral Suspension, 10mg/mL is commercially available through full-line wholesalers nationwide as of Oct 16, 2025.

Arbli is described as the first FDA-approved ready-to-use liquid losartan, targeting patients unable to swallow tablets (including elderly and children six and older). The U.S. losartan market is noted at $256M annually with 71M prescriptions, positioning Arbli as a new entrant into the broader hypertension market and a replacement for inconsistent compounded liquids.

SCIENTURE Holdings (NASDAQ: SCNX) announced on October 3, 2025 that it entered an agreement with Arena Finance Markets and Arena Special Opportunities III to fully repay and convert outstanding secured convertible debentures.

The conversion revises the debenture conversion price to $2.4861 per share, results in issuance of common stock to satisfy remaining balances, automatically releases liens and security interests, terminates the debenture documents, and deems obligations paid in full except for limited surviving items.

Company leadership said the action strengthens the balance sheet, eliminates interest-bearing obligations, and supports acceleration of commercial momentum following the first product launch.

Scienture Holdings (NASDAQ: SCNX) has secured multiple Group Purchasing Organization (GPO) agreements for Arbli™ (losartan potassium), expanding access to over 2,500 healthcare institutions, representing ~20% of the U.S. institutional market.

Arbli™ is the first FDA-approved ready-to-use oral suspension of losartan, targeting a $256M annual market with 71M prescriptions. The drug is approved for treating hypertension in patients over six years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients.

The product addresses unmet needs with its liquid formulation, eliminating compounding requirements while offering reduced dosing volume and room temperature storage stability. Arbli™ is protected by two USPTO patents listed in the FDA Orangebook.

SCIENTURE (NASDAQ:SCNX) has secured a major PBM-led GPO rebate agreement for Arbli™ (losartan potassium), their FDA-approved liquid formulation of losartan. This agreement advances formulary access with health plans covering over 100 million lives.

Arbli™ is the first and only ready-to-use liquid losartan in the U.S., targeting the $256 million losartan market with 71 million prescriptions annually. The product is approved for treating hypertension in patients over six years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients.

The proprietary formulation offers advantages including reduced dosing volume, room-temperature stability, and elimination of compounding needs, protected by two USPTO patents listed in the FDA Orangebook.